Arrowhead’s New Nanobioscience Subsidiary Plans Preclinical Studies and Collaboration with NCI

Arrowhead Research Corporation announced today that its new wholly-owned nanobioscience subsidiary has changed its name from "C Sixty Acquisition Corp." to "Tego BioSciences Corporation." The subsidiary recently acquired the assets of C Sixty, Inc. and is focused on the development of new protective products based on the anti-oxidant properties of modified buckministerfullerenes (also known as fullerenes or buckyballs). Tego is initially developing products to reduce oxidative damage caused by sun exposure, radiation therapy, and chemotherapy and mitigate complications associated with organ transplantation and tissue engineering.

"Tego is set to commence preclinical animal studies in collaboration with the National Cancer Institute this summer," said R. Bruce Stewart, Chairman of Arrowhead. "Tego is in the process of assembling a business and technical team with expertise in nanoparticle-based therapeutics and skin care products."

The preclinical studies will be performed in the NCI’s Nanotechnology Characterization Lab (NCL) to measure the ability of a Tego fullerene formulation to protect against harmful side effects of two anti-cancer drugs, cisplastin and adriamycin. The first stage of the studies will use NCL’s resources, with follow on funding from Tego, as appropriate.

The National Cancer Institute (NCI), working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), established the Nanotechnology Characterization Laboratory (ncl.cancer.gov) to perform preclinical efficacy and toxicity testing of nanoparticles. The NCL serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services to nanomaterial providers, the NCL can accelerate the transition of basic nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Arrowhead Pharmaceutical. (2019, March 19). Arrowhead’s New Nanobioscience Subsidiary Plans Preclinical Studies and Collaboration with NCI. AZoNano. Retrieved on May 23, 2024 from https://www.azonano.com/news.aspx?newsID=4328.

  • MLA

    Arrowhead Pharmaceutical. "Arrowhead’s New Nanobioscience Subsidiary Plans Preclinical Studies and Collaboration with NCI". AZoNano. 23 May 2024. <https://www.azonano.com/news.aspx?newsID=4328>.

  • Chicago

    Arrowhead Pharmaceutical. "Arrowhead’s New Nanobioscience Subsidiary Plans Preclinical Studies and Collaboration with NCI". AZoNano. https://www.azonano.com/news.aspx?newsID=4328. (accessed May 23, 2024).

  • Harvard

    Arrowhead Pharmaceutical. 2019. Arrowhead’s New Nanobioscience Subsidiary Plans Preclinical Studies and Collaboration with NCI. AZoNano, viewed 23 May 2024, https://www.azonano.com/news.aspx?newsID=4328.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.